Abstracts tagged "Hispanic patients and Sjogren’s syndrome"

Abstract Number: 503 • 2013 ACR/ARHP Annual Meeting
Sjögren’s Syndrome In American Ethnic and Racial Minorities
Ann Igoe¹, Christopher J. Lessard^2,3, Juan-Manuel Anaya⁴, Astrid Rasmussen², Kiely Grundahl⁵, Biji T. Kurien^6,7,8, Jacen S Maier-Moore⁹, Lida Radfar¹⁰, John A. Ice², Glen D. Houston¹¹, David M. Lewis¹², Donald U. Stone¹³, Kimberly S. Hefner¹⁴, Kathy L. Sivils^2,3 and R. Hal Scofield^6,8,15, ¹Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁴Center for Autoimmune Diseases Research (CREA), Universidad del Rosario., Bogota, Colombia, ⁵Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, oklahoma CIty, OK, ⁶Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁷U.S. Department of Veterans Affairs Medical Center, Oklahoma City, OK, ⁸College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁹Medicine; Arthritis & Clinical Immunology, University of Oklahoma Health Sciences Center, Oklahoma Medical Research Foundation, Department of Veterans Affairs, Oklahoma City, OK 73104, Oklahoma City, OK, ¹⁰College of Dentristry, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ¹¹Collage of Denistry, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ¹²College of Dentistry, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ¹³Department of Ophthalmology, Dean McGee Eye Institute, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ¹⁴Hefner Eye Care and Optical Center, Oklahoma City, OK, ¹⁵US Department of Veterans Affairs Medical Center, Oklahoma City, OK
Background/Purpose: Examine the racial and ethnic make-up of a large cohort of Sjögren’s syndrome (SS) gathered in the USA compared to the make-up found among…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].